Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MV 012 968

Next Previous
Drug Profile

MV 012 968

Alternative Names: MV-012-968; OE4 (RSV-A2-dNS1-dNS2-DSH-dGm)-Gsnull-line19F; Respiratory syncytial virus vaccine - Meissa Vaccine; RSV vaccine - Meissa Vaccine

Latest Information Update: 10 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Emory University
  • Developer Meissa Vaccines
  • Class Attenuated vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Respiratory syncytial virus infections

Most Recent Events

  • 08 Aug 2023 Safety and efficacy data from a phase I trial in Respiratory syncytial virus infections (prevention) released by Meissa Vaccines
  • 08 Aug 2023 Meissa plans a phase II/III trial for Respiratory syncytial virus infections (prevention) in next year
  • 28 Jul 2023 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(In children, In infants, Prevention) in USA (Intranasal, Drops)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top